Repurposing Polo-like kinase 1 or Aurora kinase A ± Wee1 inhibitors in advanced clinical developments for other indications is a therapeutic strategy worthy of being explored, to attempt to improve the outcome of patients with advanced SM. This evidence concerns the gene PLK1 and systemic mastocytosis.